Key result
Biodegradable polymer DES show similar 2-year clinical outcomes to durable polymer DES after CTO PCI.
Why the study?
Data comparing biodegradable polymer versus durable polymer drug-eluting stents in patients with chronic total occlusion undergoing successful PCI were limited.
Does the use of biodegradable polymer drug-eluting stents improve clinical outcomes compared to durable polymer drug-eluting stents in patients undergoing successful PCI for chronic total occlusion?
Does the use of biodegradable polymer drug-eluting stents improve clinical outcomes compared to durable polymer drug-eluting stents in patients undergoing successful PCI for chronic total occlusion?
Biodegradable polymer and durable polymer drug-eluting stents provide similar 2-year clinical outcomes in patients undergoing successful percutaneous coronary intervention for chronic total occlusion.
Supports either polymer stent type in CTO PCI; leaves open randomized confirmation of long-term equivalence.
Background Previous studies presented that newer generation stents implantation for coronary chronic total occlusion (CTO) improved clinical outcomes. However, there were limited data regarding comparison of the biodegradable polymer (BP) versus durable polymer (DP) drug-eluting stents (DESs) for CTO patients who underwent successful percutaneous coronary intervention (PCI). We compared major clinical outcomes following successful CTO PCI with two different type of DESs up to 2 years. Methods A total of 434 CTO patients enrolled from January 2012 were divided into two groups; BP stent group (n=228) and DP stent group (n=206). Individual and composite clinical outcomes were compared between the two groups up to 2 years. Results The baseline clinical characteristics were similar between the two groups except that BP stent group had higher prevalence of hypertension and dyslipidemia. After log-rank test showed that DP stent group had a higher incidence of total death, however after baseline adjustment by cox proportional hazards regression, there were no difference for individual and composite clinical outcomes up to 2 years (Table). Conclusions In our study, BP stent and DP stent showed similar individual and composite clinical outcomes in patients who underwent successful CTO PCI up to 2 years. Long-term and large-scale studies are needed for final conclusion.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question. Biodegradable and durable polymer drug-eluting stents showed similar clinical outcomes up to 2 years after successful PCI in 434 CTO patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: